February 9, 2007 -- Optimer had trouble finding investors in its IPO, forcing the company to keep lowering its price. But once it began trading, the stock was received warmly, producing a decent gain. Optimer concentrates on antibiotics, with two diarrhea drugs in clinical trials. Almost half the proceeds from the IPO will go to buy back the US rights for one of the drugs from Par Pharma. We look at the story...
